SCHEMBL4482936

SCHEMBL4482936

O=S(=O)(Nc1ccc2c(c1)C(C1CCNCC1)=CCO2)c1ccc(Cl)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 3/20 0.81
MAPT P10636 3/20 0.47
ATIC P31939 1/20 0.46
MGAT2 Q10469 1/20 0.44
PKM P14618 1/20 0.43
CCNT1 O60563 1/20 0.43
CDK9 P50750 1/20 0.43
PNMT P11086 1/20 0.43
ESR1 P03372 1/20 0.42
CES1 P23141 1/20 0.42
CYP19A1 P11511 1/20 0.41
GAA P10253 1/20 0.41
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6476010 0.90 HTR6 (0.81) HTR6CCNT1CDK9ESR1MEN1
SCHEMBL4480862 0.90 HTR6 (1.00) HTR6MAPTPKMCCNT1CDK9
SCHEMBL6475723 0.89 HTR6 (0.80) HTR6MAPTPKMCCNT1CDK9
Water SCHEMBL4559433 0.89 HTR6 (0.98) HTR6MAPTPKMCCNT1CDK9
Water SCHEMBL4559431 0.89 HTR6 (0.98) HTR6MAPTPKMCCNT1CDK9
SCHEMBL4487505 0.83 HTR6 (0.68) HTR6MAPTGAAHTR2CMEN1
SCHEMBL4477508 0.83 HTR6 (0.80) HTR6MAPTPKMCCNT1CDK9
SCHEMBL6472087 0.81 HTR6 (0.76) HTR6MAPTHTR2CKMT2ALMNA
SCHEMBL3324653 0.79 HTR6 (0.72) HTR6
SCHEMBL6473187 0.72 MAPT (0.54) HTR6MAPTATICPKMPNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534801-B2 Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-05-19 US claimed
US-20050107431-A1 Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-05-19 US claimed
WO-2005037830-A1 PIPERIDINYLCHROMEN-6-YLSULFONAMIDE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2005-04-28 WO claimed
US-7534801-B2 Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-05-19 US disclosed
US-20050107431-A1 Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-05-19 US disclosed
WO-2005037830-A1 PIPERIDINYLCHROMEN-6-YLSULFONAMIDE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107431-A1 Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, TPH1 HTR6 1/4885MAPT 1153/4885ATIC 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.